AlphaStocks
5.3
Consider Buy

Moderna, Inc. (MRNA)

As of Sep 20, 2026, Moderna, Inc. (MRNA) scores 5.3/10 on AlphaStocks' five-model composite, #93 of 168 Health Care stocks.

Health Care / Biotechnology

S&P 500

$153.99

Below average on several measures. Research carefully.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#93out of 168 in Health Care

Is Moderna, Inc. a Good Investment in 2026?

Moderna, Inc. (MRNA) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating Moderna, Inc. as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -12.5% · ROC -32%. Moderna, Inc. ranks #93 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-31.4Market Cap61B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -12.5% · ROC -32%

Frequently Asked Questions

Is Moderna, Inc. (MRNA) a good investment?
As of Sep 20, 2026, Moderna, Inc. (MRNA) scores 5.3/10 on AlphaStocks' five-model composite, #93 of 168 Health Care stocks. That score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Moderna, Inc.'s Piotroski F-Score?
Moderna, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is MRNA overvalued or undervalued?
A precise fair value estimate is not available for MRNA. Currently unprofitable — fair value estimate not available.
How does MRNA compare to other Health Care stocks?
Moderna, Inc. ranks #93 out of 168 stocks in the Health Care sector, placing it in the top 55% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about MRNA?
AlphaStocks evaluates MRNA using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.3/10.

Similar Stocks

ABBVINCYHRMY

Compare MRNA with

ABBV vs MRNAINCY vs MRNAHRMY vs MRNAFTI vs MRNAMRNA vs PARRMRNA vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer